Baird Financial Group
PVLA

Baird Financial Group’s Palvella Therapeutics PVLA Stock Holding History

Baird Financial Group’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,251
Closed -$2.59M – 1941
2021
Q3 		$2.59M Buy
6,251
+6,126
+4,901% +$2.13M 0.01% 838
2021
Q2 		$38K Buy
+125
New +$27.4K ﹤0.01% 1732
2018
Q4 		– Sell
-2,176
Closed -$933K – 1372
2018
Q3 		$933K Buy
2,176
+17
+0.8% +$7.39K 0.01% 870
2018
Q2 		$876K Buy
2,159
+60
+3% +$28.6K 0.01% 861
2018
Q1 		$1.15M Buy
2,099
+1,309
+166% +$810K 0.01% 790
2017
Q4 		$477K Buy
+790
New +$367K ﹤0.01% 1029

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Baird Financial Group's PVLA Position: Q4 2021 in Review

Baird Financial Group sold out of Palvella Therapeutics (PVLA) in Q4 2021, closing a stake of 6,251 shares — an estimated $2.59M sold.

Baird Financial Group first reported a position in PVLA in Q4 2017 and held it in 6 quarters. The position peaked at $2.59M in Q3 2021. 81 funds tracked by Wall St. Rank hold PVLA as of Q4 2021.

  • Baird Financial Group reported no remaining Palvella Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Baird Financial Group sold 6,251 Palvella Therapeutics shares in Q4 2021, an estimated $2.59M.
  • Baird Financial Group first reported a position in Palvella Therapeutics in Q4 2017 and held it in 6 quarters.
  • Baird Financial Group's Palvella Therapeutics position peaked at $2.59M in Q3 2021.
  • 81 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2021.

Based on Baird Financial Group's 13F filing for Q4 2021, filed 9 Feb 2022.